Physician profile
Rohit Bhalla
NPI 1962604819
$7,378.72
in general payments reported to CMS, 2019-2025
31 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $634 · 2021: $1,210 · 2022: $1,110 · 2023: $1,183 · 2024: $1,425 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,913 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,912.72 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,845.41 | 2019-2025 | Biktarvy, Epclusa, Yeztugo |
| Organogenesis INC. | $1,537.51 | 2019-2025 | Affinity, Apligraf, Puraply Wound Matrix |
| Viiv Healthcare Company | $940.67 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $585.58 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $402.70 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $280.69 | 2020-2024 | Nuzyra |
| Abbvie INC. | $219.39 | 2021-2025 | Dalvance, Mavyret |
| Aimmune Therapeutics, INC. | $215.55 | 2023-2025 | Vowst |
| Urgo Medical North America, LLC | $198.18 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Smith+Nephew, INC. | $183.18 | 2019-2024 | Collagenase Santyl |
| Janssen Biotech, INC. | $140.23 | 2020-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $111.09 | 2021-2025 | Zevtera, Xacduro |
| Janssen Products, Lp | $99.00 | 2022 | |
| Shionogi INC | $86.87 | 2022-2025 | Fetroja |
| Vertos Medical, INC. | $74.78 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $74.51 | 2022-2025 | Trogarzo, Egrifta |
| Novo Nordisk INC | $71.20 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $46.10 | 2019-2020 | |
| Grifols USA, LLC | $36.23 | 2025 | Xembify |
| Ferring Pharmaceuticals INC. | $30.26 | 2022-2024 | Rebyota |
| Tactile Systems Technology INC | $25.80 | 2023 | Entre Plus, Flexitouch Plus |
| Molnlycke Health Care US, LLC | $24.83 | 2022 | |
| Hydrofera LLC | $24.10 | 2021 | |
| Solventum Corporation | $22.95 | 2025 | Activ.A.C., 3m Coban |
| Pfizer INC. | $16.84 | 2025 | |
| Kerecis Limited | $16.12 | 2019 | |
| Nabriva Therapeutics, Plc | $14.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.93 | 2021 | |
| Integra Lifesciences Corporation | $13.75 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.56 | 2025 | Vibativ |
| Horizon Therapeutics Plc | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.